Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tripartite Therapeutics Inc. currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions that require attention. These actions are distributed across 2 distinct examiners, indicating that each pending matter is being reviewed by a different official at the patent office. This distribution suggests a lack of examiner-level concentration in the current pipeline.
The 2 pending office actions are also situated within 2 distinct art units. This separation across different art units implies that the company's intellectual property filings cover diverse technical sub-fields within the broader biotechnology sector. KARL J PUTTLITZ is identified as the busiest examiner for the company, currently overseeing 1 pending action. This figure represents 1 of the 2 total pending actions for the portfolio.
With only 2 pending actions across 2 distinct examiners and 2 distinct art units, the prosecution footprint is relatively small. Practitioners should note that the busiest examiner, KARL J PUTTLITZ, is only handling 1 pending action, which is the same volume as the other examiner involved. This one-to-one ratio between actions and examiners highlights the individualized nature of the company's current interactions with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19407141 | LIGAND-DRUG CONJUGATES | PUTTLITZ, KARL J | — |
| 18205841 | LIGAND-POLAR DRUG CONJUGATES | HERNANDEZ, JACKSON J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19407141 | LIGAND-DRUG CONJUGATES | PUTTLITZ, KARL J | — |
| 18205841 | LIGAND-POLAR DRUG CONJUGATES | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19407141 | LIGAND-DRUG CONJUGATES | PUTTLITZ, KARL J | 1646 | §102§112 | Final Rejection | — | Pending | Dec 03, 2025 |
| 18205841 | LIGAND-POLAR DRUG CONJUGATES | HERNANDEZ, JACKSON J | 1627 | §102§103§112 | Non-Final OA | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTripartite Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Karl J Puttlitz has the most, with 1 of Tripartite Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
